Skip to content

Iberdomide (Zenbexus) for multiple myeloma.

Unknown authors
Oct 2026 · The Medical letter on drugs and therapeutics · Vol 68 1766, pp. e175-e176 · 0 citations
Medicine

Abstract

Iberdomide (Zenbexus – BMS), an oral first-in-class cereblon-modulating protein degrader, has received accelerated approval from the FDA for use in combination with the CD38-directed cytolytic antibody daratumumab (Darzalex Faspro) and dexamethasone for treatment of multiple myeloma in adults who received at least one prior line of therapy, including a proteasome inhibitor (e.g., bortezomib) and an immunomodulatory drug. The drug was approved based on a surrogate endpoint of minimal residual disease-negative complete response.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.